10-Q: 60 Degrees Pharmaceuticals Q1 2026 Financials Show Revenue Dip, Increased Spending

60 Degrees Pharmaceuticals reported a slight decrease in product revenue for Q1 2026, alongside increased operating expenses, while continuing to focus on its infectious disease pipeline and managing its cash position.

Summary

• 60 Degrees Pharmaceuticals reported product revenues of $162,092 for the three months ended March 31, 2026, a slight decrease from $163,552 in the same period of 2025.
• Cost of revenues increased to $85,715 from $73,272, leading to a decrease in gross profit to $76,377 from $90,280.
• Research revenues were nil in Q1 2026, compared to $92,731 in Q1 2025, due to the completion of USAMMDA-funded activities.
• Total operating expenses increased to $2,171,338 from $2,093,949, driven by higher general and administrative expenses.
• The company reported a net loss of $2,089,214 for the period, compared to a net loss of $1,876,549 in the prior year.
• Cash and cash equivalents increased to $3,337,760 from $1,510,065, but the company continues to face substantial doubt about its ability to continue as a going concern.
• Net proceeds from At-The-Market (ATM) offerings in Q1 2026 totaled $2,535,047.
• The company regained compliance with Nasdaq's minimum bid price requirement after implementing a 1:4 reverse stock split in January 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, increased expenses, a widening net loss, and significant going concern issues, despite some positive business development activities and Nasdaq compliance.

Positives

• The company successfully regained compliance with Nasdaq's minimum bid price requirement following a 1:4 reverse stock split.
• Cash and cash equivalents increased significantly to $3,337,760 as of March 31, 2026, from $1,510,065 as of December 31, 2025, bolstered by ATM offerings.
• Partnerships were established with Runway Health and GoodRx to expand access and offer discounts for Arakoda.
• Positive results were announced for the babesiosis trial, with all three enrolled patients cured.
• A New Dietary Ingredient Notification (NDIN) was submitted to the FDA for Australian Chestnut Extract.

Negatives

• Product revenues saw a slight decrease of 0.89% to $162,092 in Q1 2026 compared to $163,552 in Q1 2025.
• Gross margin decreased to 47.12% from 55.20%, resulting in a $13,903 decline in gross profit.
• Research revenues dropped to $0 from $92,731 due to the completion of USAMMDA-funded activities.
• Operating expenses increased by 3.70% to $2,171,338, primarily due to a 9.68% rise in general and administrative expenses.
• The company reported a net loss of $2,089,214 for the quarter, an increase from the $1,876,549 net loss in the prior year.
• Substantial doubt remains regarding the company's ability to continue as a going concern, with insufficient funds projected to last beyond mid-September 2026 without additional capital raises.
• Sales volume for Arakoda decreased by 19% in equivalent 16-ct boxes sold to pharmacies and dispensaries.

Risks

• The company faces substantial doubt about its ability to continue as a going concern, with insufficient funds projected to last beyond mid-September 2026 without additional capital raises.
• Failure to maintain compliance with Nasdaq's continued listing requirements, including the minimum bid price rule, could lead to delisting, adversely affecting liquidity and market price.
• The company is subject to risks common to the biopharmaceutical industry, including product development, regulatory approval, market adoption, and significant competition.
• Increases in interest rates and economic uncertainty may heighten risks.
• If additional banks and financial institutions become insolvent, the company's ability to access existing cash, cash equivalents, and investments may be threatened.
• A failure to perform by current distributors in Australia and Europe could create disruption for patients.
• If the sole vendor for tafenoquine ceases supply, it would require significant costs and efforts to rebuild the supply chain.
• The company may need to raise additional capital, but there is no assurance it will be able to do so on acceptable terms, or at all.
• Debt and equity financing may involve covenants that limit the company's actions.
• Collaborations or similar arrangements may require relinquishing valuable rights or granting unfavorable licenses.
• Inability to raise additional funds may require delaying, limiting, reducing, or terminating product development or commercialization efforts.

Future Outlook

The company estimates it will have sufficient funds to remain viable through mid-September 2026, assuming no additional capital raises. However, based on current cash forecasts and planned operating expenditures, it does not have sufficient cash to fund its operating plan for at least the next 12 months, raising substantial doubt about its ability to continue as a going concern. Management plans to fund operations through third-party and related-party debt/advances, private placements, and stock issuances until profitability or a business combination is achieved. The company expects to use net proceeds from ATM offerings for general corporate purposes, including working capital, commercialization support for Arakoda, and funding babesiosis clinical development programs.

Management Comments

• The company announced its partnership with Runway Health to expand pre-departure access to Arakoda for malaria prevention.
• The company commenced its partnership with GoodRx to offer eligible patients savings on Arakoda.
• The company announced that all three enrolled patients were cured of babesiosis after completing the tafenoquine regimen in its trial.
• The company submitted a New Dietary Ingredient Notification (NDIN) to the FDA for Australian Chestnut Extract.

Industry Context

StockSavvy.ai notes that 60 Degrees Pharmaceuticals operates in the highly competitive biopharmaceutical sector, focusing on infectious diseases. The company's Q1 2026 results reflect typical challenges faced by early-stage biopharma companies, including significant R&D expenses, reliance on capital raises, and the long path to commercialization. The focus on vector-borne diseases and specific conditions like malaria and babesiosis aligns with niche market strategies within the broader infectious disease landscape.

Comparison to Industry Standards

• Compared to larger pharmaceutical companies with established product portfolios and consistent revenue streams, 60 Degrees Pharmaceuticals exhibits a typical early-stage biopharma profile with significant net losses and reliance on external financing.
• The company's gross margin of 47.12% for Q1 2026 is lower than the industry average for established pharmaceutical manufacturers, which often exceed 70-80%, reflecting higher cost of goods sold relative to revenue at this stage.
• The net loss of $2,089,214 is substantial relative to its revenue, a common characteristic for companies investing heavily in research and development, as seen in many clinical-stage biotechs.
• The company's cash burn rate of $2,741,559 for operating activities in Q1 2026 is a critical metric to monitor, as it directly impacts runway. Many clinical-stage biotechs aim to manage this burn rate through efficient R&D spending and strategic partnerships, similar to the collaborations 60 Degrees Pharmaceuticals is pursuing.

Legal Proceedings

• There were no reportable litigation events during the quarter ended March 31, 2026.

Stakeholder Impact

• Shareholders: The company's continued reliance on equity financings and the ongoing net losses may impact share value. Regaining Nasdaq compliance is a positive step, but the going concern issue remains a significant concern.
• Employees: Continued funding challenges could impact future hiring and resource allocation for R&D and commercialization efforts.
• Creditors: The company's ability to meet its financial obligations is dependent on its ability to raise capital, which could impact creditors if not successful.
• Distributors/Partners: The success of partnerships like Runway Health and GoodRx is crucial for Arakoda's market penetration and revenue generation.

Next Steps

• Continue negotiations for the full license agreement with Florida State University (FSU) for castanospermine extraction techniques.
• Monitor FDA's response to the New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract, with a decision expected by May 25, 2026.
• Continue to fund operations through planned capital raises and potential business development transactions.
• Support commercialization efforts for Arakoda and fund babesiosis clinical development programs.
• Evaluate the impact of new accounting standards (ASU 2024-03, ASU 2025-06, ASU 2025-07).

Key Dates

Recommendation

The company has regained Nasdaq compliance and secured new partnerships, which are positive developments. However, the significant net loss, ongoing cash burn, and substantial doubt about its ability to continue as a going concern present considerable risks. The current situation warrants a 'hold' recommendation, pending clearer signs of revenue growth, improved financial stability, and successful progression of its development pipeline.

Keywords

60 Degrees Pharmaceuticals, Form 10-Q, Quarterly Report, Arakoda, Tafenoquine, Malaria Prevention, Infectious Diseases, Biopharmaceutical, Financial Results, Net Loss, Going Concern, ATM Offering, Nasdaq Compliance, Babesiosis Trial